US20030092691A1 - Pharmaceutical composition based on micronized progesterone, method for the preparation thereof and uses thereof - Google Patents

Pharmaceutical composition based on micronized progesterone, method for the preparation thereof and uses thereof Download PDF

Info

Publication number
US20030092691A1
US20030092691A1 US10/097,526 US9752602A US2003092691A1 US 20030092691 A1 US20030092691 A1 US 20030092691A1 US 9752602 A US9752602 A US 9752602A US 2003092691 A1 US2003092691 A1 US 2003092691A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
progesterone
oil
oestradiol
preferentially
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/097,526
Inventor
Jerome Besse
Antoine Besins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Besins International Belgique
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Assigned to BESINS INTERNATIONAL BELGIQUE reassignment BESINS INTERNATIONAL BELGIQUE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BESINS, ANTOINE, BESSE, JEROME
Publication of US20030092691A1 publication Critical patent/US20030092691A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Definitions

  • the present invention relates to a pharmaceutical composition containing micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin. It also relates to pharmaceutical products comprising said pharmaceutical composition.
  • the invention also relates to the method for manufacturing this pharmaceutical composition, as well as to the uses thereof.
  • Progesterone is a hormone which is synthesized, in women, essentially by the ovary during the post-ovulation or luteal phase (more precisely by the cells of the corpus luteum) and, to a lesser degree, by the adrenal glands and the placenta during the second part of pregnancy. Non-endocrine synthesis of progesterone, in particular in neurons, is also possible.
  • progesterone insufficiency A consequence of insufficiency of progesterone secretion in a woman is a loss of its biological effects: progestative effect, anti-androgen effect (action on the skin) and anti-oestrogen effect (the consequence being high oestrogen production: hot flushes, psychogenic difficulties of the anxious or depressive type, weight gain, etc.).
  • This progesterone insufficiency may lead to functional difficulties and diverse clinical manifestations, in particular:
  • progesterone suffers from a serious handicap due to the poor intestinal absorption and to the intense hepatic metabolism (short plasmatic half-life) of this hormone. Only the vaginal, rectal and intramuscular pathways would, to date, make it possible to maintain blood progesterone level at the physiological level of the luteal phase, for several hours.
  • the LABORATOIRES BESINS-ISCOVESCO have already proposed a solution in order to improve the quality and intensity of the digestive absorption of natural progesterone, in Patent Application FR 76 36007. Specifically, they have developed a formulation of soft capsules containing micronized progesterone in oily suspension. The synergistic effect of the micronization and the use of molecules containing long-chain fatty acids has made it possible to indisputably increase the bioavailability of progesterone taken orally. This formulation has known a great deal of success worldwide. It is sold in France under the trade mark UTROGESTAN®.
  • the oil which serves as a basis for the oily suspension in UTROGESTAN® is peanut oil.
  • Peanut Arachis hypogae is a leguminous plant, a bushy annual plant with yellow flowers, of the Papilionacea family.
  • UTROGESTAN® may be prescribed in many cases of therapeutic indications, including as a supplement to the luteal phase during cycles of in vitro fertilization (IVF), and in the case of a danger of abortion or of prevention of repeat abortion due to luteal insufficiency, up to the 12th week of pregnancy. It is therefore possible, in theory, for a foetus to be exposed to UTROGESTAN® in utero.
  • IVF in vitro fertilization
  • the micronized progesterone is preferably in suspension in sunflower oil and/or in olive oil.
  • U.S. Pat. No. 5,140,021 only describes a laboratory scale preparation of the progesterone capsules and provides no teaching regarding the preparation of capsules on an industrial scale.
  • the progesterone capsules according to said American patent do not contain soya bean lecithin, which is an essential element of the pharmaceutical composition according to the present invention.
  • the soya bean lecithin plays the role of an agent for suspending the progesterone particles in the sunflower oil and of a lubricant during encapsulation of the content on an industrial scale.
  • the invention therefore relates to a pharmaceutical composition
  • a pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin.
  • the micronized progesterone is in suspension in sunflower oil and/or olive oil.
  • micronized progesterone is intended to mean a progesterone in which at least 80% of the particles have a particle size of between 1 and 15 ⁇ m, preferably 50% of the particles have a particle size of between 1 and 10 ⁇ m, and even more preferentially 25% of the particles have a particle size of between 1 and 5 ⁇ m, these particle sizes being measured using a laser particle sizer of the Malvern type, by the procedure described in the examples of the present patent application.
  • the particle size was not the same in the presence or absence of the soya bean lecithin.
  • the main advantage of the sunflower oil and/or the olive oil in physicochemical terms compared to the peanut oil is to simultaneously ensure both:
  • the progesterone/oil(s) ratio is between 0.15/1 and 3/1, preferably between 0.25/1 and 2/1, preferentially between 0.40/1 and 1/1, and even more preferentially is 0.67/1.
  • the soya bean lecithin/oil(s) ratio is between 0.005/1 and 0.3/1, preferably between 0.01/1 and 0.2/1, preferentially between 0.040/1 and 0.1/1, and even more preferentially is 0.067/1.
  • the pharmaceutical composition according to the invention may also comprise an oestrogen, preferably selected from the group consisting of 17- ⁇ -oestradiol, oestrone, 17- ⁇ -ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17- ⁇ -oestradiol.
  • an oestrogen preferably selected from the group consisting of 17- ⁇ -oestradiol, oestrone, 17- ⁇ -ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17- ⁇ -oestradiol.
  • the pharmaceutical composition according to the invention may be in the form, inter alia, of a soft capsule, of a hard capsule or of a tablet.
  • each dosage unit advantageously comprises between 2 mg and 600 mg of micronized progesterone, preferably between 30 mg and 300 mg, and even more preferentially between 100 mg and 200 mg.
  • composition according to the invention may be administered orally or vaginally, depending on the therapeutic indications.
  • Vaginal administration also represents an alternative to oral administration in the case of side effects due to the progesterone (drowsiness after oral absorption) or of contraindication to oral administration (hepatopathy).
  • the capsule comprises gelatin or an equivalent.
  • the invention also relates to a method for preparing a pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin.
  • This method comprises the following successive steps:
  • micronized progesterone is added, with stirring, to the mixture thus obtained in order to obtain a homogeneous suspension.
  • This suspension may be conditioned directly in the form of soft capsules, but may also be used to impregnate an absorbent support presented in the form of powder.
  • This absorbent support may be of the maltodextrin and/or derivatives, silica and/or derivatives, cyclodextrin and/or derivatives or cellulose powder and/or derivatives type, or a combination thereof, or any other pharmaceutical raw material which possesses equivalent properties.
  • the powder thus obtained may then be presented in the form of hard capsules or tablets.
  • the hard capsules or tablets containing the powder may also comprise binding agents, disintegrating agents, diluents and/or lubricants.
  • the invention also relates to the use of the micronized progesterone, of the sunflower oil and/or the olive oil, and of the soya bean lecithin, for preparing a medicinal product for treating a physiological condition linked to insufficiency of progesterone secretion.
  • luteal insufficiency Menstrual irregularity, premenstrual syndromes, mastodynia, benign mastopathies, premenopause, sterility due to luteal insufficiency, disorders due to menopause, local contraception, for prevention of repeated abortions in the case of luteal insufficiency, danger of premature birth, acne, alopecia, for prevention of osteoporosis, endometrial cancers and epilepsy.
  • the invention also relates to the use of the micronized progesterone, of the sunflower oil and/or olive oil, and of the soya bean lecithin, and also an oestrogen, for preparing a medicinal product for treating a physiological condition linked to insufficiency of progesterone secretion.
  • the oestrogen is preferably selected from the group consisting of 17- ⁇ -oestradiol, oestrone, 17- ⁇ -ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17- ⁇ -oestradiol.
  • the applicant company has also prepared 500 mg capsules which are homothetic with the 250 mg capsules described above.
  • the 500 mg capsules contain 200 mg of micronized progesterone, 298 mg of sunflower oil and 2 mg of soya bean lecithin.
  • sunflower oil with a high oleic acid content sunflower oil with a high oleic acid content
  • Standard solutions were prepared as follows: - concentrated solution: progesterone batch A0098 10 mg oil qs for 20 ml - diluted solution: concentrated solution 1 ml tetrahydrofuran (THF) 10 ml acetonitrile qs for 20 ml magnetic stirring: 5 minutes.
  • the capsules are prepared according to one of the methods known per se to those skilled in the art.
  • the atmosphere is controlled at 22° C. ⁇ 3° C. and at a relative humidity of 35% ⁇ 10%.
  • a mixer with a volume of 600 litres is placed under vacuum.
  • the mixer is again placed under vacuum (between 0.7 bar and 0.9 bar), followed by stirring at low speed between 10 rpm and 15 rpm.
  • progesterone is added under vacuum, followed by the remaining quarter of sunflower oil, and the temperature is brought to 23° C. ⁇ 3° C.
  • the mixer with vigorous stirring is placed under a pressure up to a maximum of 1 bar.
  • the storage containers are placed under vacuum and then stirred at between 2400 and 2000 rpm for 15 minutes. They are again placed under vacuum and restirred for 30 minutes at a speed of between 2000 and 2500 rpm.
  • Amount of sample per measurement 1 or 2 drops deposited using a pipette
  • Medium filtered saturated sunflower oil. This oil is prepared with magnetic stirring, maintaining the temperature at 37° C., for 1 hour, and then filtered on filter paper.
  • control solution is filtered on a fibreglass syringe filter with a porosity of 1 ⁇ m.

Abstract

The present invention relates to a pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin, to the method for the preparation thereof and to the uses thereof for treating a physiological condition linked to insufficiency of progesterone secretion.

Description

  • The present invention relates to a pharmaceutical composition containing micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin. It also relates to pharmaceutical products comprising said pharmaceutical composition. [0001]
  • The invention also relates to the method for manufacturing this pharmaceutical composition, as well as to the uses thereof. [0002]
  • Progesterone is a hormone which is synthesized, in women, essentially by the ovary during the post-ovulation or luteal phase (more precisely by the cells of the corpus luteum) and, to a lesser degree, by the adrenal glands and the placenta during the second part of pregnancy. Non-endocrine synthesis of progesterone, in particular in neurons, is also possible. [0003]
  • A consequence of insufficiency of progesterone secretion in a woman is a loss of its biological effects: progestative effect, anti-androgen effect (action on the skin) and anti-oestrogen effect (the consequence being high oestrogen production: hot flushes, psychogenic difficulties of the anxious or depressive type, weight gain, etc.). This progesterone insufficiency may lead to functional difficulties and diverse clinical manifestations, in particular: [0004]
  • premenstrual syndromes, [0005]
  • menstrual irregularities due to disovulation or anovulation, [0006]
  • benign mastopathies, [0007]
  • perimenopause and menopause. [0008]
  • However, oral administration of progesterone suffers from a serious handicap due to the poor intestinal absorption and to the intense hepatic metabolism (short plasmatic half-life) of this hormone. Only the vaginal, rectal and intramuscular pathways would, to date, make it possible to maintain blood progesterone level at the physiological level of the luteal phase, for several hours. [0009]
  • The LABORATOIRES BESINS-ISCOVESCO have already proposed a solution in order to improve the quality and intensity of the digestive absorption of natural progesterone, in Patent Application FR 76 36007. Specifically, they have developed a formulation of soft capsules containing micronized progesterone in oily suspension. The synergistic effect of the micronization and the use of molecules containing long-chain fatty acids has made it possible to indisputably increase the bioavailability of progesterone taken orally. This formulation has known a great deal of success worldwide. It is sold in France under the trade mark UTROGESTAN®. [0010]
  • The oil which serves as a basis for the oily suspension in UTROGESTAN® is peanut oil. [0011]
  • Peanut ([0012] Arachis hypogae) is a leguminous plant, a bushy annual plant with yellow flowers, of the Papilionacea family.
  • In the last 15 years, peanut allergy has become a considerable allergological problem. [0013]
  • Dutau et al. (La Presse Medicale [Medical Press], vol. 28, p. 1553) observe that the prevalence of peanut allergy has recently been estimated at 1.3% in the general population. The increased use of peanut in food, very often in a masked form, perhaps explains this development. [0014]
  • Early sensitizations have been described in infants who have never consumed peanuts in conventional form, but who were apparently sensitized in utero or via maternal milk, through maternalized milks having contained plant fats (peanut oil) or through medicinal preparations in oily solution. [0015]
  • UTROGESTAN® may be prescribed in many cases of therapeutic indications, including as a supplement to the luteal phase during cycles of in vitro fertilization (IVF), and in the case of a danger of abortion or of prevention of repeat abortion due to luteal insufficiency, up to the 12th week of pregnancy. It is therefore possible, in theory, for a foetus to be exposed to UTROGESTAN® in utero. [0016]
  • To date, while the allergenic effects of peanut are definite, a controversy still exists regarding the ability of peanut oil to engender allergenic reactions. Many publications may be cited on this subject, including: Taylor et al., J. Allergy Clin. Immunol., vol. 68, p. 372 (1981); Moneret-Vautrin et al., Pediatr. Allergy Immunol. vol. 5, p. 184 (1994); Sabbah and Lauret, Allergie et Immunologie, vol. 26, p. 380 (1994); de Montis et al., Arch. Pediatr., vol. 2. p. 25 (1995)). [0017]
  • Given this fact, the applicant company devoted itself to developing a novel pharmaceutical composition, replacing the peanut oil with other oils which do not have high risks of allergenicity, while at the same time endeavouring to conserve the advantages of the prior formula. [0018]
  • After much study and research, during which several plant oils were tested, sunflower oil and olive oil were selected. Specifically, the use of these oils makes it possible to rule out the risks of allergic reactions, while at the same time conserving all of the physicochemical and kinetic characteristics of the prior UTROGESTAN® formulation, characteristics which were the cause of its success. Given that the method for manufacturing the prior UTROGESTAN® formulation on an industrial scale comprise steps which are very delicate to carry out, it is to the credit of the applicant company to have succeeded in modifying the formulation without increasing the production difficulties. [0019]
  • In the pharmaceutical composition according to the invention, the micronized progesterone is preferably in suspension in sunflower oil and/or in olive oil. [0020]
  • The applicant company is aware of U.S. Pat. No. 5,140,021 in the name of GENESIS SYSTEMS CORPORATION (Maxson et al.) which describes a soft capsule containing a micronized progesterone in suspension in a highly unsaturated oil. Sunflower oil appears among the oils cited in this patent. However, the inventors of this patent U.S. Pat. No. 5,140,021 have taken the greatest care to distinguish themselves from the pharmaceutical product UTROGESTAN®, i.e. the formulation developed and currently marketed by the applicant company, based on peanut oil. Thus, the micronized progesterone used in the GENESIS SYSTEMS patent is described as having a particular particle size distribution which is different from that used in UTROGESTAN®. [0021]
  • U.S. Pat. No. 5,140,021 only describes a laboratory scale preparation of the progesterone capsules and provides no teaching regarding the preparation of capsules on an industrial scale. In addition, the progesterone capsules according to said American patent do not contain soya bean lecithin, which is an essential element of the pharmaceutical composition according to the present invention. Specifically, the soya bean lecithin plays the role of an agent for suspending the progesterone particles in the sunflower oil and of a lubricant during encapsulation of the content on an industrial scale. [0022]
  • The invention therefore relates to a pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin. [0023]
  • According to an advantageous embodiment of the pharmaceutical composition according to the invention, the micronized progesterone is in suspension in sunflower oil and/or olive oil. [0024]
  • In the context of the present invention, the term “micronized progesterone” is intended to mean a progesterone in which at least 80% of the particles have a particle size of between 1 and 15 μm, preferably 50% of the particles have a particle size of between 1 and 10 μm, and even more preferentially 25% of the particles have a particle size of between 1 and 5 μm, these particle sizes being measured using a laser particle sizer of the Malvern type, by the procedure described in the examples of the present patent application. [0025]
  • During the studies prior to choosing the oil, the applicant company was able to observe, surprisingly and unexpectedly, that the combination of soya bean lecithin with sunflower oil and/or olive oil was very advantageous since it did not modify the particle size of the micronized progesterone in suspension in the oil. In addition, no significant difference in the particle size distribution of the micronized progesterone in suspension became apparent between the composition based on peanut oil and that containing sunflower oil and/or olive oil, these oils being used in accordance with the invention. [0026]
  • With regard to the other oils tested, the particle size was not the same in the presence or absence of the soya bean lecithin. The main advantage of the sunflower oil and/or the olive oil in physicochemical terms compared to the peanut oil is to simultaneously ensure both: [0027]
  • comparable solubilities at saturation of the micronized progesterone; [0028]
  • comparable particle sizes of the suspension; [0029]
  • and comparable in vitro dissolution profiles. [0030]
  • Now, particle size and solubility at saturation significantly influence the in vivo bioavailability of the progesterone. [0031]
  • The choice of these oils therefore makes it possible to have better control of the particle size distribution of the micronized progesterone in the oily suspension, and also the amount of progesterone solubilized in the oil, and therefore to bring together all of the conditions required for maintaining an in vivo bioavailability similar to that obtained with UTROGESTAN®. [0032]
  • According to an advantageous embodiment of the pharmaceutical composition according to the invention, the progesterone/oil(s) ratio is between 0.15/1 and 3/1, preferably between 0.25/1 and 2/1, preferentially between 0.40/1 and 1/1, and even more preferentially is 0.67/1. [0033]
  • According to an advantageous embodiment of the pharmaceutical composition of the invention, the soya bean lecithin/oil(s) ratio is between 0.005/1 and 0.3/1, preferably between 0.01/1 and 0.2/1, preferentially between 0.040/1 and 0.1/1, and even more preferentially is 0.067/1. [0034]
  • The pharmaceutical composition according to the invention may also comprise an oestrogen, preferably selected from the group consisting of 17-β-oestradiol, oestrone, 17-α-ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17-β-oestradiol. [0035]
  • The pharmaceutical composition according to the invention may be in the form, inter alia, of a soft capsule, of a hard capsule or of a tablet. [0036]
  • When the pharmaceutical composition according to the invention is integrated into a pharmaceutical product, each dosage unit advantageously comprises between 2 mg and 600 mg of micronized progesterone, preferably between 30 mg and 300 mg, and even more preferentially between 100 mg and 200 mg. [0037]
  • The pharmaceutical composition according to the invention may be administered orally or vaginally, depending on the therapeutic indications. [0038]
  • Vaginal administration also represents an alternative to oral administration in the case of side effects due to the progesterone (drowsiness after oral absorption) or of contraindication to oral administration (hepatopathy). [0039]
  • According to an advantageous embodiment of the pharmaceutical composition according to the invention, the capsule comprises gelatin or an equivalent. [0040]
  • The invention also relates to a method for preparing a pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin. [0041]
  • This method comprises the following successive steps: [0042]
  • mixing of sunflower and/or olive oil and of soya bean lecithin is carried out, with stirring, in order to obtain a mixture; [0043]
  • the micronized progesterone is added, with stirring, to the mixture thus obtained in order to obtain a homogeneous suspension. [0044]
  • This suspension may be conditioned directly in the form of soft capsules, but may also be used to impregnate an absorbent support presented in the form of powder. [0045]
  • This absorbent support may be of the maltodextrin and/or derivatives, silica and/or derivatives, cyclodextrin and/or derivatives or cellulose powder and/or derivatives type, or a combination thereof, or any other pharmaceutical raw material which possesses equivalent properties. [0046]
  • The powder thus obtained may then be presented in the form of hard capsules or tablets. The hard capsules or tablets containing the powder may also comprise binding agents, disintegrating agents, diluents and/or lubricants. [0047]
  • The invention also relates to the use of the micronized progesterone, of the sunflower oil and/or the olive oil, and of the soya bean lecithin, for preparing a medicinal product for treating a physiological condition linked to insufficiency of progesterone secretion. [0048]
  • As examples of such physiological conditions, mention may be made of: luteal insufficiency, menstrual irregularity, premenstrual syndromes, mastodynia, benign mastopathies, premenopause, sterility due to luteal insufficiency, disorders due to menopause, local contraception, for prevention of repeated abortions in the case of luteal insufficiency, danger of premature birth, acne, alopecia, for prevention of osteoporosis, endometrial cancers and epilepsy. [0049]
  • The invention also relates to the use of the micronized progesterone, of the sunflower oil and/or olive oil, and of the soya bean lecithin, and also an oestrogen, for preparing a medicinal product for treating a physiological condition linked to insufficiency of progesterone secretion. The oestrogen is preferably selected from the group consisting of 17-β-oestradiol, oestrone, 17-α-ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17-β-oestradiol. [0050]
  • The invention will be more clearly understood using the nonlimiting examples described below.[0051]
    • EXAMPLE 1 Pharmaceutical Composition in the Form of a Soft Capsule According to the Invention
  • The content of a soft capsule according to the invention is described in Table I below. [0052]
    TABLE I
    Percentage References
    formula (%) to
    Compound name per unit (mg) Function standards
    Active substance
    Micronized 40.00 100.00 Active Ph.Eur.3rd
    progesterone substance ed.
    Excipients
    Sunflower oil 59.60 149.00 Diluent Ph.Eur.3rd
    and/or olive ed.
    oil
    Soya bean  0.40  1.00 Emulsifier USP 24, NF
    lecithin 19, p.2471
  • The applicant company has also prepared 500 mg capsules which are homothetic with the 250 mg capsules described above. Thus, the 500 mg capsules contain 200 mg of micronized progesterone, 298 mg of sunflower oil and 2 mg of soya bean lecithin. [0053]
    • EXAMPLE 2 Study of Solubility of Micronized Progesterone in Various Oils
  • In order to select the optimum oily vehicle to replace the peanut oil, while at the same time conserving the physicochemical properties of the prior formulation, the following plant oils were tested with regard to the solubility of progesterone in these oils: [0054]
  • peanut oil [0055]
  • olive oil [0056]
  • refined olive oil [0057]
  • sunflower oil [0058]
  • sunflower oil with a high oleic acid content [0059]
  • rapeseed oil [0060]
  • Standard solutions were prepared as follows: [0061]
    - concentrated solution: progesterone batch A0098 10 mg
    oil qs for 20 ml
    - diluted solution: concentrated solution  1 ml
    tetrahydrofuran (THF) 10 ml
    acetonitrile qs for 20 ml
    magnetic stirring: 5 minutes.
  • The saturated solutions were then prepared as follows: [0062]
  • The saturated solutions in each oil were maintained for one hour with stirring at room temperature, and were then filtered on a nylon filter syringe with a diameter of 25 mm, at 0.45 μm. [0063]
  • Saturated solutions were diluted 200-fold: [0064]
    - saturated solution:  0.5 ml
    - THF:  50 ml
    - acetonitrile qs for 100 ml
  • The results are given in Table II below: [0065]
    TABLE II
    CONCENTRATION AT SATURATION
    OIL TESTED (mg/ml)
    Peanut oil 16.77
    Rapeseed oil 18.14
    Sunflower oil 17.50
    Sunflower oil with a high  8.29
    oleic acid content
    Olive oil 17.46
    Refined olive oil 19.56
  • The sunflower, olive and refined olive oils were selected following this study of solubility at saturation. [0066]
  • Among the various suppliers of oils mention may be made, by way of example, of: [0067]
  • for the olive oil: LESSIEUR; [0068]
  • for the sunflower oil: HENRY LAMOTTE. [0069]
    • EXAMPLE 3 Manfacturing of Soft Micronized ProgesteronE Capsules According to the Invention
  • The manufacturing of the soft capsules based on micronized progesterone according to the invention is carried out as follows: [0070]
  • The capsules are prepared according to one of the methods known per se to those skilled in the art. [0071]
  • For a batch of 2 300 000 capsules, each containing 100 mg of progesterone, the following procedure is carried out: [0072]
  • The atmosphere is controlled at 22° C.±3° C. and at a relative humidity of 35%±10%. [0073]
  • The following ingredients are weighed: [0074]
    Progesterone 230.00 kg
    Sunflower oil 342.70 kg
    Soya bean lecithin  2.30 kg
  • A mixer with a volume of 600 litres is placed under vacuum. [0075]
  • Three quarters of the amount of sunflower oil is introduced under vacuum into this mixer and the soya bean lecithin is added. [0076]
  • The mixer is again placed under vacuum (between 0.7 bar and 0.9 bar), followed by stirring at low speed between 10 rpm and 15 rpm. [0077]
  • The progesterone is added under vacuum, followed by the remaining quarter of sunflower oil, and the temperature is brought to 23° C.±3° C. [0078]
  • Next, vigorous stirring is carried out until homogenization is obtained. [0079]
  • The mixer with vigorous stirring is placed under a pressure up to a maximum of 1 bar. [0080]
  • Continuous sieving using a 500 μm sieve is carried out and the mixture is transferred into a storage container. [0081]
  • The storage containers are placed under vacuum and then stirred at between 2400 and 2000 rpm for 15 minutes. They are again placed under vacuum and restirred for 30 minutes at a speed of between 2000 and 2500 rpm. [0082]
  • The stirring is stopped and the containers are left to stand for 5 minutes under vacuum. [0083]
  • The encapsulation is carried out in a conventional manner known to those skilled in the art. [0084]
    • EXAMPLE 4 Determination of the Particle Size of a Capsule According to the invention
  • A comparative particle size study was carried out between UTROGESTRAN® capsules and capsules according to the invention containing sunflower oil. [0085]
  • The material used is as follows: [0086]
  • Mastersizer 2000 laser particle sizer [0087]
  • Hydro 2000 SM measuring cell [0088]
  • according to the following method: [0089]
  • Amount of sample per measurement: 1 or 2 drops deposited using a pipette [0090]
  • Medium: filtered saturated sunflower oil. This oil is prepared with magnetic stirring, maintaining the temperature at 37° C., for 1 hour, and then filtered on filter paper. [0091]
  • Refractive index: (oil average) 1.4671 [0092]
  • Medium volume: 100 ml [0093]
  • Stirring rate: 1800 rpm [0094]
  • Percentage obscuration: between 10 and 20% [0095]
  • Weighted residual percentage: <3% [0096]
  • Number of measurements per preparation: 2. The measurements begin after the percentage obscuration has been stable for 30 min. [0097]
  • The results given in FIG. 1 hereinafter demonstrate that the particle sizes of the two capsules are highly comparable. [0098]
    • EXAMPLE 5 Comparative in Vitro Dissolution Study Between a UTROGESTRAN® Capsule and a Capsule According to the Invention
  • A SOTAX AT7 dissolution machine with rotating baskets was used. [0099]
  • 20 mg of exactly weighed progesterone are dissolved in 2 ml of ethanol, in a 200 ml volumetric flask (class A), this is then treated with ultrasound and the volume is made up to the capacity line using the dissolution medium (1% Kleptose). [0100]
  • The control solution is filtered on a fibreglass syringe filter with a porosity of 1 μm. [0101]
  • 7 tanks are placed in a waterbath at constant temperature, and then 1000 ml of dissolution medium are transferred into each of the 7 tanks. [0102]
  • 1 capsule is placed in 6 tanks, and then the baskets are immersed in the dissolution medium at a distance of 25 mm±2 mm between the basket and the bottom of the tank. [0103]
  • The baskets are stirred, and then a control solution is prepared. [0104]
  • At each time interval planned (5, 10, 15, 30, 45, 60, 90, 120, 150, 180, 225, 270, 315 and 360 minutes), the samples are collected and then analysed by UV spectrophotometry (X: 248 nm). [0105]
  • The results given in FIG. 2 hereinafter demonstrate that the in vitro dissolution curves for an UTROGESTAN® capsule and for a capsule according to the invention containing sunflower oil are virtually identical. [0106]
  • The physicochemical characteristics of the prior formulation are therefore conserved in the formulation according to the invention. [0107]

Claims (9)

1. Pharmaceutical composition comprising micronized progesterone, sunflower oil and/or olive oil, and soya bean lecithin.
2. Pharmaceutical composition according to claim 1, in which the progesterone/oil(s) ratio is between 0.15/1 and 3/1, preferably between 0.25/1 and 2/1, preferentially between 0.40/1 and 1/1, and even more preferentially is 0.67/1.
3. Pharmaceutical composition according to claim 1, in which the soya bean lecithin/oil(s) ratio is between 0.005/1 and 0.3/1, preferably between 0.01/1 and 0.2/1, preferentially between 0.040/1 and 0.1/1, and even more preferentially is 0.067/1.
4. Pharmaceutical composition according to claim 1, comprising an oestrogen, preferably selected from the group consisting of 17-β-oestradiol, oestrone, 17-α-ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17-β-oestradiol.
5. Pharmaceutical composition according to claim 1, in the form of a soft capsule, of a hard capsule or of a tablet.
6. Pharmaceutical product according to claim 1, in which each dosage unit comprises between 2 mg and 600 mg of micronized progesterone, preferably between 30 mg and 300 mg, and even more preferentially between 100 mg and 200 mg.
7. Method for preparing a pharmaceutical composition according to claim 1, comprising the following successive steps:
mixing of sunflower and/or olive oil and of soya bean lecithin is carried out, with stirring, in order to obtain a mixture;
the micronized progesterone is added, with stirring, to the mixture thus obtained in order to obtain a homogeneous suspension.
8. Method of treatment of a physiological condition linked to insufficiency of progesterone secretion, comprising the step of administering a pharmaceutical composition according to claim 1 to the subject.
9. Method of treatment according to claim 8, in which the pharmaceutical composition also contains an oestrogen, preferably selected from the group consisting of 17-β-oestradiol, oestrone, 17-α-ethinyl oestradiol and oestradiol valerianate, and even more preferentially is 17-β-oestradiol.
US10/097,526 2001-11-13 2002-03-14 Pharmaceutical composition based on micronized progesterone, method for the preparation thereof and uses thereof Abandoned US20030092691A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0114653 2001-11-13
FR0114653A FR2832065B1 (en) 2001-11-13 2001-11-13 PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF

Publications (1)

Publication Number Publication Date
US20030092691A1 true US20030092691A1 (en) 2003-05-15

Family

ID=8869332

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/097,526 Abandoned US20030092691A1 (en) 2001-11-13 2002-03-14 Pharmaceutical composition based on micronized progesterone, method for the preparation thereof and uses thereof
US10/495,242 Expired - Lifetime US7431941B2 (en) 2001-11-13 2002-11-13 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US12/071,822 Expired - Lifetime US7829115B2 (en) 2001-11-13 2008-02-27 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US12/916,795 Abandoned US20110135719A1 (en) 2001-11-13 2010-11-01 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US13/542,164 Expired - Lifetime US8435561B2 (en) 2001-11-13 2012-07-05 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof

Family Applications After (4)

Application Number Title Priority Date Filing Date
US10/495,242 Expired - Lifetime US7431941B2 (en) 2001-11-13 2002-11-13 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US12/071,822 Expired - Lifetime US7829115B2 (en) 2001-11-13 2008-02-27 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US12/916,795 Abandoned US20110135719A1 (en) 2001-11-13 2010-11-01 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
US13/542,164 Expired - Lifetime US8435561B2 (en) 2001-11-13 2012-07-05 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof

Country Status (25)

Country Link
US (5) US20030092691A1 (en)
EP (1) EP1443940B1 (en)
KR (1) KR100911790B1 (en)
CN (1) CN1263453C (en)
AT (1) ATE339958T1 (en)
AU (1) AU2002352334B2 (en)
BR (1) BRPI0214043B8 (en)
CY (1) CY1106293T1 (en)
DE (1) DE60214876T2 (en)
DK (1) DK1443940T3 (en)
EA (1) EA006550B1 (en)
ES (1) ES2272793T3 (en)
FR (1) FR2832065B1 (en)
HK (1) HK1064606A1 (en)
HU (1) HU229341B1 (en)
IL (2) IL161668A0 (en)
MA (1) MA27081A1 (en)
NO (1) NO335044B1 (en)
NZ (1) NZ532659A (en)
OA (1) OA12726A (en)
PL (1) PL206096B1 (en)
PT (1) PT1443940E (en)
UA (1) UA77451C2 (en)
WO (1) WO2003041720A1 (en)
ZA (1) ZA200403288B (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060275360A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Oral dosage forms comprising progesterone and methods of making and using the same
JP2007523872A (en) * 2003-07-17 2007-08-23 バナー ファーマキャップス，インコーポレイティド Controlled release formulation
US20080188829A1 (en) * 2007-02-06 2008-08-07 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2832065B1 (en) * 2001-11-13 2004-11-05 Besins Int Belgique PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF
EP2055306A1 (en) * 2007-11-05 2009-05-06 Bayer Schering Pharma AG Application of a gestagen in combination with an oestrogen and one or more pharmaceutically acceptable excipients/media for lactose-free oral contraception
FR2947178B1 (en) * 2009-06-29 2012-07-06 Effik PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE AND USES THEREOF
CN102091054B (en) * 2009-12-14 2014-04-16 浙江爱生药业有限公司 Progesterone preparation composite and preparation method thereof
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
DK2755498T3 (en) * 2011-09-15 2018-05-22 Friulchem Spa COMPOSITION FOR ORAL ADMINISTRATION FOR ANIMALS AND PROCEDURE FOR OBTAINING
CA2850187C (en) 2011-09-29 2021-12-07 Plx Pharma Inc. Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
JP2018522854A (en) 2015-06-22 2018-08-16 リポカイン インコーポレーテッド Oral compositions containing 17-hydroxyprogesterone esters and related methods
EP3395332A1 (en) * 2017-04-28 2018-10-31 Chemo Research, S.L. Hormone softgel capsules and a process for the preparation thereof
US11576920B2 (en) 2019-03-18 2023-02-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
KR20220158031A (en) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 Pharmaceutical carrier capable of pH dependent reconstitution and method of manufacturing and using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408345A1 (en) * 1976-11-30 1979-06-08 Besins Jean Louis NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION
JPS60258110A (en) * 1984-06-05 1985-12-20 Daigo Eiyou Kagaku Kk Progesterone emulsified parenteral solution injectable intravenously
US5140021A (en) * 1986-04-16 1992-08-18 Genesis Systems Corporation Method and dosage form for treatment of premenstrual syndrome
IE61236B1 (en) * 1986-07-15 1994-10-19 American Home Prod Combination dosage form for pre-menopausal women
IT1256386B (en) * 1992-11-13 1995-12-04 Luigi Boltri PHARMACEUTICAL COMPOSITIONS INCLUDING A DRUG, A CROSS-LINKED POLYMERIC SUBSTANCE, AN OIL AND A SURFACTIVE AGENT
DE69402297T2 (en) * 1993-12-22 1997-07-10 Oreal Cosmetic or dermatological powder, process for its preparation and uses
FR2747042B1 (en) * 1996-04-05 1998-06-05 Besins Iscovesco Lab PROGESTERONE AND OESTRADIOL-BASED MEDICINE
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
JP4260886B2 (en) * 1996-05-01 2009-04-30 アメリカ合衆国 21-Substituted progesterone derivatives as novel anti-progesterone
FR2777784B1 (en) * 1998-04-27 2004-03-19 Arepa PHARMACEUTICAL COMPOSITION BASED ON ESTROGEN AND PROGESTERONE
FR2832065B1 (en) * 2001-11-13 2004-11-05 Besins Int Belgique PHARMACEUTICAL COMPOSITION BASED ON MICRONIZED PROGESTERONE, PREPARATION METHOD THEREOF AND USES THEREOF

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523872A (en) * 2003-07-17 2007-08-23 バナー ファーマキャップス，インコーポレイティド Controlled release formulation
US8663681B2 (en) 2005-05-26 2014-03-04 Teva Women's Health, Inc. Oral dosage forms comprising progesterone and methods of making and using the same
US20060275360A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Oral dosage forms comprising progesterone and methods of making and using the same
US7884093B2 (en) 2007-02-06 2011-02-08 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US20080188829A1 (en) * 2007-02-06 2008-08-07 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9248136B2 (en) 2011-11-23 2016-02-02 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US8846648B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8846649B2 (en) 2011-11-23 2014-09-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987237B2 (en) 2011-11-23 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10675288B2 (en) 2011-11-23 2020-06-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11103516B2 (en) 2011-11-23 2021-08-31 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11793819B2 (en) 2011-11-23 2023-10-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11865179B2 (en) 2012-06-18 2024-01-09 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US11166963B2 (en) 2012-06-18 2021-11-09 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9289382B2 (en) 2012-06-18 2016-03-22 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9012434B2 (en) 2012-06-18 2015-04-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10052386B2 (en) 2012-06-18 2018-08-21 Therapeuticsmd, Inc. Progesterone formulations
US11529360B2 (en) 2012-06-18 2022-12-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10639375B2 (en) 2012-06-18 2020-05-05 Therapeuticsmd, Inc. Progesterone formulations
US11110099B2 (en) 2012-06-18 2021-09-07 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9006222B2 (en) 2012-06-18 2015-04-14 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11033626B2 (en) 2012-06-18 2021-06-15 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8987238B2 (en) 2012-06-18 2015-03-24 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471148B2 (en) 2012-06-18 2019-11-12 Therapeuticsmd, Inc. Progesterone formulations having a desirable PK profile
US8933059B2 (en) 2012-06-18 2015-01-13 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11304959B2 (en) 2012-12-21 2022-04-19 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11622933B2 (en) 2012-12-21 2023-04-11 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11497709B2 (en) 2012-12-21 2022-11-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11351182B2 (en) 2012-12-21 2022-06-07 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10835487B2 (en) 2012-12-21 2020-11-17 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10888516B2 (en) 2012-12-21 2021-01-12 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11065197B2 (en) 2012-12-21 2021-07-20 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11241445B2 (en) 2012-12-21 2022-02-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11123283B2 (en) 2012-12-21 2021-09-21 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11116717B2 (en) 2012-12-21 2021-09-14 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11103513B2 (en) 2014-05-22 2021-08-31 TherapeuticsMD Natural combination hormone replacement formulations and therapies
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10098894B2 (en) 2014-07-29 2018-10-16 Therapeuticsmd, Inc. Transdermal cream
US10668082B2 (en) 2014-10-22 2020-06-02 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10398708B2 (en) 2014-10-22 2019-09-03 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10258630B2 (en) 2014-10-22 2019-04-16 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10912783B2 (en) 2015-07-23 2021-02-09 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10532059B2 (en) 2016-04-01 2020-01-14 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Also Published As

Publication number Publication date
DK1443940T3 (en) 2007-01-29
HK1064606A1 (en) 2005-02-04
ATE339958T1 (en) 2006-10-15
CY1106293T1 (en) 2011-10-12
IL161668A0 (en) 2004-09-27
CN1585644A (en) 2005-02-23
BRPI0214043B8 (en) 2021-05-25
KR20050058231A (en) 2005-06-16
UA77451C2 (en) 2006-12-15
HU229341B1 (en) 2013-11-28
US7829115B2 (en) 2010-11-09
FR2832065A1 (en) 2003-05-16
FR2832065B1 (en) 2004-11-05
EP1443940B1 (en) 2006-09-20
BR0214043A (en) 2004-10-13
WO2003041720A1 (en) 2003-05-22
US20120276194A1 (en) 2012-11-01
EA200400668A1 (en) 2004-10-28
US7431941B2 (en) 2008-10-07
OA12726A (en) 2006-06-27
CN1263453C (en) 2006-07-12
NZ532659A (en) 2006-04-28
US20050004076A1 (en) 2005-01-06
PT1443940E (en) 2007-01-31
US8435561B2 (en) 2013-05-07
EA006550B1 (en) 2006-02-24
MA27081A1 (en) 2004-12-20
HUP0401935A3 (en) 2011-02-28
US20090123534A1 (en) 2009-05-14
NO335044B1 (en) 2014-09-01
ES2272793T3 (en) 2007-05-01
DE60214876D1 (en) 2006-11-02
DE60214876T2 (en) 2007-04-05
PL206096B1 (en) 2010-06-30
AU2002352334B2 (en) 2008-10-23
NO20042002L (en) 2004-05-14
IL161668A (en) 2009-09-01
EP1443940A1 (en) 2004-08-11
BRPI0214043B1 (en) 2019-12-31
ZA200403288B (en) 2005-07-27
PL369131A1 (en) 2005-04-18
KR100911790B1 (en) 2009-08-12
HUP0401935A2 (en) 2005-01-28
US20110135719A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
US8435561B2 (en) Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
KR20120037363A (en) Micronised progesterone pharmaceutical composition and uses thereof
JPH05502457A (en) Kava kava extracts, their manufacturing process and uses
RU2709209C1 (en) Agent with vitamin d3 for treating ulcerative colitis in the form of rectal suppositories
CN110101707B (en) Composition for improving hypofunction of ovarian reserve and preventing premature ovarian failure and application thereof
JP2014508158A (en) Treatment of vaginal atrophy as a novel indication for myrrh
RU2220712C1 (en) Agent and set for normalization of functional disorders arising in preclimacteric and climacteric period
WO2018222164A9 (en) Use of an herbal formula containing pumpkin seed oil in bph treatment
JP2003277274A (en) Agent having female hormone-like action
US11058737B2 (en) Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females
JP7409939B2 (en) Premenstrual weight gain suppressant
CN109260209B (en) Calcitriol soft capsule and preparation method thereof
RU2219904C2 (en) Vaginal suppository with antifungal effect (variants)
JPH0351390B2 (en)
DE202023002046U1 (en) The prophylaxis of cardiovascular problems such as aggregation of platelets and arteriosclerosis as well as bone loss and the reduction of libido in older men through the combined administration of the plant estrogen 8-prenylnaringenin with acetyl-salicylic acid
CN114848650A (en) Stable estazolam preparation composition and preparation method thereof
JP3987663B2 (en) Herbal medicine-containing composition with improved disintegration
RU2246297C2 (en) Gelatin capsule &#34;gastrobiol-tsd&#34; based on sea-buckthorn oil concentrate clathrates eliciting anti-ulcer effect
RU2205019C1 (en) &#34;mamoclam&#34; preparation for treating mastopathy
DE3411910A1 (en) Pharmaceutical formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: BESINS INTERNATIONAL BELGIQUE, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BESSE, JEROME;BESINS, ANTOINE;REEL/FRAME:012849/0977;SIGNING DATES FROM 20020328 TO 20020405

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION